Clinical Trials

7 enrolled

Melanoma

NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

DermatologicGastrointestinalHead & Neck

72 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

NCT02562625 2026-04-23

PERM

Phase 2 Terminated

17 enrolled 14 charts

Melanoma

NCT04207086 2026-04-23

Neo PeLe

21 enrolled

Melanoma

NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Terminated

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT03149029 2026-04-21

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

16 enrolled 10 charts

Melanoma

NCT06545682 2026-04-16

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

Phase 1 Recruiting

50 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

DermatologicHead & NeckThoracic

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

Phase 1 Completed

12 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT02816021 2026-04-06

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

24 enrolled

Melanoma

NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

25 enrolled 16 charts

Melanoma

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

10 enrolled

Phase EARLY_PHASE1 Completed

Melanoma

NCT03276832 2026-03-19

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

7 enrolled 11 charts

Melanoma

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

36 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Phase 1 Recruiting

36 enrolled

Melanoma

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

14 enrolled

Melanoma

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07448831 2026-03-09

NeoSenti

49 enrolled

Melanoma

NCT07436390 2026-03-02

MAK

Phase NA Completed

132 enrolled

Melanoma, Skin Neoplasms

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

2 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

26 enrolled

Melanoma

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Melanoma

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

22 enrolled

Phase 1/2 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT07376317 2026-01-29

OTIMAS

29 enrolled

Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

Recruiting

30 enrolled

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

20 enrolled

Melanoma

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

Phase 1/2 Recruiting

135 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

24 enrolled 13 charts

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

BreastDermatologicSarcoma

14 enrolled

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT04129515 2026-01-02

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Phase 1/2 Withdrawn

Phase 1/2 Active not recruiting

Melanoma

NCT03131908 2025-12-15

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

27 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03595683 2025-12-08

Pembrolizumab and EDP1503 in Advanced Melanoma

Phase 2 Terminated

8 enrolled 10 charts

DermatologicHead & NeckSarcoma

Melanoma

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Phase 1 Recruiting

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT05282901 2025-11-24

PLUME

51 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1/2 Terminated

34 enrolled 18 charts

Melanoma

NCT06906822 2025-09-18

PlugIN

60 enrolled

Melanoma

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Recruiting

270 enrolled

Melanoma, Skin Neoplasms

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)